Trial Profile

Efficacy and safety of Tocilizumab in systemic sclerosis patients: the EUSTAR Database analysis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary)
Indications Systemic scleroderma
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

05 Jun 2021 Primary endpoint (Primary endpoints are mRSS (modified Rodnan Skin Score) and FVC, both at 12 months follow-up time.) has not been met, according to Results presented at the 22nd Annual Congress of the European League Against Rheumatism.
05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.
22 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com